Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1470-2045(19)30543-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Purpose: Patients with advanced, well-differentiated extrapancreatic neuroendocrine tumors (epNETs) have limited systemic treatment options. Pazopanib, an oral multikinase inhibitor with activity against vascular endothelial growth factor receptor (VEGFR)-2 and -3, PDGFR-alpha and-beta, and c-Kit, was tested for efficacy in epNET.
Patients And Methods: We conducted a multicenter, randomized, double-blind, phase II study of pazopanib (800 mg once daily) versus placebo in low- to intermediate-grade epNET with radiologic progressive disease (PD) within 12 months of study entry.
Thyroid Fibrosarcoma as a Rare Differential Diagnosis of Anaplastic Thyroid Cancer: A Case Report.
Case Rep Endocrinol
August 2025
Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.
Thyroid gland fibrosarcomas are very rare tumors, with only very few cases have been reported in the literature. Their similarity to anaplastic thyroid cancer poses a diagnostic challenge, often leading to misdiagnosis. We report the case of an 87-year-old female with a history of left thyroid nodule who underwent a left lobectomy and subsequently, received levothyroxine therapy.
View Article and Find Full Text PDFCommon molecular links and therapeutic insights between type 2 diabetes and kidney cancer.
PLoS One
August 2025
Bioinformatics Lab (Dry), Department of Statistics, University of Rajshahi, Rajshahi, Bangladesh.
Introduction: Type 2 diabetes (T2D) is considered as a risk factor for kidney cancer (KC). However, so far, there is no study in the literature that has explored genetic factors through which T2D drive the development and progression of KC. Therefore, this study attempted to explore T2D- and KC-causing shared key genes (sKGs) for revealing shared pathogenesis and therapeutic drugs as their common treatments.
View Article and Find Full Text PDFRelative Dose Intensity of Trabectedin and Outcome of Advanced L-Sarcomas.
Cancer Med
August 2025
Department of Medical Oncology, Centre Oscar-Lambret, Lille, France.
Background: Trabectedin, which is approved for advanced soft tissue sarcoma management, has a complex mechanism of action, but can be classified as an alkylating agent. The need to maintain a high relative dose intensity (RDI) is not clearly established in this clinical setting.
Methods: We conducted a retrospective study in five expert centers to compare the progression-free survival (PFS) and overall survival (OS) of patients with advanced L-Sarcomas (liposarcomas or leiomyosarcoma) according to the RDI calculated over the first three cycles (RDI < 80% and RDI ≥ 80%).
Impact of concomitant use of pazopanib and gastric acid suppressants on progression-free survival and safety in patients with sarcoma: a retrospective study.
J Pharm Health Care Sci
August 2025
Department of Pharmacy, Kameda Medical Center, 929 Higashi-Cho, Kamogawa, Chiba, 296-8602, Japan.
Background: Pazopanib (PAZ) is an oral multi-kinase inhibitor used in the treatment of advanced soft tissue sarcoma. Gastric acid suppressants such as proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RAs) may reduce PAZ absorption by increasing gastric pH, potentially affecting its efficacy. This study aimed to evaluate the impact of concomitant use of acid suppressants on progression-free survival (PFS) and safety in patients with soft tissue sarcoma.
View Article and Find Full Text PDF